for Lung Cancer
Personalized, tumor-informed testing for molecular residual disease (MRD) to inform lung cancer care across the treatment journey.
Know More, Sooner
Identify High Risk Patients
Test for presence of MRD after definitive therapy to assess prognosis1-2
sensitivity for predicting recurrence1-2
Detect Recurrence Earlier
Detect recurrence before radiographic imaging1-2
mean lead time over radiographic recurrence1-2
Monitor Treatment Response
Track changes in ctDNA levels to evaluate treatment response3
for patients who cleared ctDNA during IO (immunotherapy)3
Evaluate Response to ICI Treatment
ICIs (immune checkpoint inhibitors) are FDA-approved with guideline recommendations across all treatment settings in lung cancer (neoadjuvant, adjuvant, locally advanced, metastatic).4
The Signatera™ Residual Disease Test was evaluated in the INSPIRE trial, a randomized, prospective study in patients with advanced or metastatic solid malignancies receiving an anti-PD-1 treatment:3
An increase in ctDNA levels from baseline to week 6 strongly predicted disease progression and nonresponse to treatment.3
Overall survival was 100% in patients who experienced ctDNA clearance for at least one on-treatment time point.3
Inform Your Lung Cancer Treatment Approach With Signatera™
Monitoring circulating tumor DNA (ctDNA) with Signatera™ across the treatment journey can answer important clinical questions and inform treatment decisions.
Do More With Less Tissue
One tumor sample – two tests
Reassure Your Patients Living With Lung Cancer
After JoAnn was diagnosed with lung cancer, Signatera™ detected a rise in her ctDNA levels, alerting her oncologist to a progression that was not scannable.
Watch JoAnn’s story to learn how she and her oncologist added Signatera™ testing to their toolbelt to help closely monitor her cancer.
“I want to know. The more you know, the better off you are.” – JoAnn, living with lung cancer
Enroll Your Lung Cancer Patients in the BESPOKE IO Trial
The BESPOKE IO clinical study is a trial for patients living with NSCLC and other solid tumor types who will receive standard of care treatment with ICIs. The study will determine how serial Signatera™ testing impacts treatment decisions and early detection of disease progression when integrated as part of routine assessment of tumor response.
Lung Cancer Resources
Signatera™ is covered by Medicare for immunotherapy treatment response monitoring across all solid tumor types and stages of cancer.
IO Monitoring Brochure
Learn how Signatera™ can assess immunotherapy response as early as 6 weeks into treatment for patients with solid tumors.3
Patient Case Study
Read how Signatera™ detected a rise in ctDNA levels during immunotherapy, informing the decision to pivot to a combination therapy approach.
Ready to try Signatera™ for your lung cancer patients?
1Abbosh C, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. https://doi.org/10.1038/nature22364
2Lebow ES, et al. Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy. Journal of Clinical Oncology 2022 40:16_suppl, 8540-8540. https://doi.org/10.1200/JCO.2022.40.16_suppl.8540
3Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873-881. https://doi.org/10.1038/s43018-020-0096-5
4NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 3.2022